Abstract 370: Contrast-Induced Nephropathy and Long-Term Outcomes in Patients With Diabetes Undergoing Coronary and Peripheral Angiography and Intervention

2017 ◽  
Vol 37 (suppl_1) ◽  
Author(s):  
Dennis A Hopkinson ◽  
Samuel P Powell ◽  
Raveen Chawla ◽  
Wendy Bottinor ◽  
Jeremy S Turlington ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Diabetic Group ◽  
Diabetic Patients ◽  
Long Term Outcomes ◽  
Peripheral Angiography ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage

Background: Patients with diabetes may be at increased risk of contrast-induced nephropathy (CIN) when undergoing coronary and/or peripheral angiography or intervention but there is little data on long-term outcomes. We examined the relationship between diabetes, CIN and long-term outcomes in patients undergoing coronary and/or peripheral angiography and intervention. Methods and Results: We studied 4070 consecutive, predominantly (98%) male patients undergoing coronary and peripheral angiography and intervention and assessed the association between diabetes, CIN and long-term outcomes including renal dysfunction at 3 months, the need for dialysis and mortality. The mean age of the patients was 66.6 years. Approximately two fifths of the patients (n=1671, 41.05%) were diabetic. Patients with diabetes were the same age but had higher baseline creatinine compared to the patients without diabetes. CIN occurred in 70 (4.19%) diabetic patients and in 64 (2.67%) patients without diabetes at 72 hours after the procedure (odds ratio [OR] 1.59; 95% confidence interval [CI] 1.13 - 2.25; P=0.008). At 3 months, renal dysfunction was seen in 179 (10.71%) diabetic patients versus 174 (7.25%) of the non-diabetic group (OR 1.53, CI 1.23 - 1.91; P=0.0001). After a follow-up of 5 years, 31 (1.86 %) patients with diabetes had developed end-stage renal disease and were started on dialysis versus 13 (0.54 %) of the non-diabetic group (OR 3.47, CI 1.81 - 6.65; P<0.0001). 478 (28.61 %) patients of the diabetic group had died versus 479 (19.97 %) of the non-diabetic group (OR 1.61, CI 1.39 - 1.86; P<0.0001). On multivariate analysis, after adjustment for age, comorbidities, medical therapy and baseline creatinine, the presence of diabetes was significantly associated with CIN (OR 1.50, CI 1.06 - 2.43: p=0.02) and was significantly associated with the incidence of end stage renal disease requiring dialysis (OR 3.64, CI 2.07-10.04; P<0.0001) and with mortality at 5 years (OR 1.58, CI 1.42-2.03, P<0.0001). Conclusion: In this cohort of patients undergoing coronary and/or peripheral angiography and intervention diabetes was associated with CIN, with end-stage renal disease and the need for hemodialysis and was associated with an increased mortality.

scholarly journals SHORT AND LONG-TERM OUTCOMES OF DIFFERENT REVASCULARIZATION STRATEGIES IN PATIENTS WITH END STAGE RENAL DISEASE ON HEMODIALYSIS

2012 ◽  
Vol 59 (13) ◽  
pp. E549 ◽  
Author(s):  
Abel E. Moreyra ◽  
Peter Hynes ◽  
Yingzi Deng ◽  
Nora M. Cosgrove ◽  
Christopher Brown ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Long Term Outcomes ◽  
Short And Long Term ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Long-term outcomes of end-stage renal disease patients admitted to the ICU

2011 ◽  
Vol 26 (9) ◽  
pp. 2965-2970 ◽  
Author(s):  
M. M. Sood ◽  
L. Miller ◽  
P. Komenda ◽  
M. Reslerova ◽  
J. Bueti ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Long Term Outcomes ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015

2020 ◽  
Author(s):  
Hui-Teng Cheng ◽  
Xiaoqi Xu ◽  
Paik Seong Lim ◽  
Kuan-Yu Hung
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Annual Incidence ◽  
Western Pacific ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
The Western Pacific

Objective <p>The annual risk among diabetic patients to reach end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015.</p> <p>Research Design and Methods</p> <p>The annual incidence of ESRD among diabetic patients was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtracting the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated using the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively.</p> <p>Results</p> <p>Data were obtained from 142 countries, covering 97·3% of the world population. The global percentage of the prevalent ESRD patients with DM increased from 19·0% in 2000 to 29·7% in 2015 worldwide, while the percentage of incident ESRD patients due to DM increased from 22·1% to 31·3%. The global annual incidence of ESRD among DM patients increased from 375·8 to 1016·0/million with DM during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European DM patients ranged from half (309·2 vs 544·6) to a third (419·4 vs 1245·2) of the rates of the Western Pacific population during 2000–2015.</p> <p>Conclusions </p> <p>Great and nonrandom geographic variation in the annual rates among diabetic patients to reach ESRD suggests that distinct healthcare, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat DM-related ESRD require better patient susceptibility stratification.</p>

scholarly journals Evaluation of long-term outcomes of deceased donor renal transplantation in patients with end-stage renal disease

2019 ◽  
Vol 8 (2) ◽  
pp. 29-29
Author(s):  
Jaiju James Chakola ◽  
Varun Mamidi ◽  
Vamsi Krishna Makkena ◽  
Jayakumar Matcha ◽  
Ramprasad Elumalai
Keyword(s):  
Renal Transplantation ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Deceased Donor ◽  
Long Term Outcomes ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Long-Term Outcomes After Carotid Artery Stenting in Patients With End-Stage Renal Disease

2015 ◽  
Vol 62 (3) ◽  
pp. 804 ◽  
Author(s):  
Isibor Arhuidese ◽  
Tammam Obeid ◽  
Caitlin Hicks ◽  
Umair Qazi ◽  
Dorry Segev ◽  
...  
Keyword(s):  
Carotid Artery ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Carotid Artery Stenting ◽  
Long Term Outcomes ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Long‐Term Outcomes of Transcatheter Aortic Valve Replacement in Patients With End‐Stage Renal Disease

2021 ◽  
Author(s):  
Takuya Ogami ◽  
Paul Kurlansky ◽  
Hiroo Takayama ◽  
Yuming Ning ◽  
Ziad A. Ali ◽  
...  
Keyword(s):  
Aortic Valve ◽  
Aortic Valve Replacement ◽  
Renal Disease ◽  
Valve Replacement ◽  
End Stage Renal Disease ◽  
Long Term Outcomes ◽  
Transcatheter Aortic Valve ◽  
Stage Renal Disease ◽  
End Stage

Background Aortic stenosis is prevalent in end‐stage renal disease. Transcatheter aortic valve replacement (TAVR) is a plausible alternative for surgical aortic valve replacement. However, little is known regarding long‐term outcomes in patients with end‐stage renal disease who undergo TAVR. Methods and Results We identified all patients with end‐stage renal disease who underwent TAVR from 2011 through 2016 using the United States Renal Data System. The primary end point was 5‐year mortality after TAVR. Factors associated with 1‐ and 5‐year mortality were analyzed. A total of 3883 TAVRs were performed for patients with end‐stage renal disease. Mortality was 5.8%, 43.7%, and 88.8% at 30 days, 1 year, and 5 years, respectively. Case volumes increased rapidly from 17 in 2011 to 1495 in 2016. Thirty‐day mortality demonstrated a dramatic reduction from 11.1% in 2012 to 2.5% in 2016 ( P =0.01). Age 75 or older (hazard ratio [HR], 1.14; 95% CI, 1.05–1.23 [ P =0.002]), body mass index <25 (HR, 1.18; 95% CI, 1.08–1.28 [ P <0.001]), chronic obstructive pulmonary disease (HR, 1.25; 95% CI, 1.1–1.35 [ P <0.001]), diabetes mellitus as the cause of dialysis (HR, 1.22; 95% CI, 1.11–1.35 [ P <0.001]), hypertension as the cause of dialysis (HR, 1.17; 95% CI, 1.06–1.29 [ P =0.004]), and White race (HR, 1.17; 95% CI, 1.06–1.3 [ P =0.002]) were independently associated with 5‐year mortality. Conclusions Short‐term outcomes of TAVR in patients with end‐stage renal disease have improved significantly. However, long‐term mortality of patients on dialysis remains high.

scholarly journals Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015

2020 ◽  
Author(s):  
Hui-Teng Cheng ◽  
Xiaoqi Xu ◽  
Paik Seong Lim ◽  
Kuan-Yu Hung
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Annual Incidence ◽  
Western Pacific ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Stage Renal Disease ◽  
End Stage ◽  
Esrd Patients ◽  
The Western Pacific

Objective <p>The annual risk among diabetic patients to reach end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015.</p> <p>Research Design and Methods</p> <p>The annual incidence of ESRD among diabetic patients was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtracting the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated using the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively.</p> <p>Results</p> <p>Data were obtained from 142 countries, covering 97·3% of the world population. The global percentage of the prevalent ESRD patients with DM increased from 19·0% in 2000 to 29·7% in 2015 worldwide, while the percentage of incident ESRD patients due to DM increased from 22·1% to 31·3%. The global annual incidence of ESRD among DM patients increased from 375·8 to 1016·0/million with DM during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European DM patients ranged from half (309·2 vs 544·6) to a third (419·4 vs 1245·2) of the rates of the Western Pacific population during 2000–2015.</p> <p>Conclusions </p> <p>Great and nonrandom geographic variation in the annual rates among diabetic patients to reach ESRD suggests that distinct healthcare, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat DM-related ESRD require better patient susceptibility stratification.</p>

Sign in / Sign up

Export Citation Format

Share Document